MARKET WIREYahoo! Finance Canada • 22h ago
AVITA Medical, Inc. (RCEL) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Avita Medical Inc. (RCEL) market action, institutional positioning, and fundamental catalysts.
Why RCEL Stock dropped -6.34% Today — RQD Quant Desk Flash
$15.65 -6.34% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $15.44
Avita Medical Inc. (RCEL) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $484.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on RCEL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is RCEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Avita Medical Inc. (NASDAQ: RCEL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $15.65 (-6.34% 1D, market cap $484.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RCEL ranks #332 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does RCEL compare to DCTH and SSII in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), RCEL carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of 82.1%, and ROIC of -35.0%. By comparison, DCTH (Delcath Systems Inc.) holds a C- grade (59/100 RQD, P/E N/A, ROIC 0.8%, cap $487.2M) and SSII (SS Innovations International Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -18.5%, cap $471.1M). Among the 5-stock peer group, RCEL leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for RCEL?
▼
Per RCEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001762303), Avita Medical Inc. generated $71.6M in revenue (+11.5% YoY), -$48.6M in net income, and -$32.2M in free cash flow against $56.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $15.44 (-1.33%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-5.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RCEL)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY RCEL SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (35% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (24% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$13.36+3.3% Next Q
38
Q2 (-2Q)Grade D$13.80+16.5% Next Q
41
Q3 (-1Q)Grade D$16.08-2.7% Next Q
43
CurrentGrade D$15.65-6.1% Hist 90D α
46
Trajectory: E (38) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a RCEL Turnaround Squeeze
While RCEL currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Big institutional funds and options desks are actively positioning on the bullish side.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.46) and Max Pain ($16.43) forces dealer call-delta covering toward $17.75.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $RCEL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RCEL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why RCEL Stock dropped -6.34% Today — RQD Quant Desk Flash
Avita Medical Inc. (RCEL) dropped -6.34% to $15.65, trading at 91% of its 52-week range ($3.22 – $16.9). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 91% of its 52-week range ($3.22 – $16.9) with RSI-14 at 61.1 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $15.65 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 82.1% gross margin and $0 annual free cash flow.
Live RCEL Headlines & Catalysts
MARKET WIREMoomoo • 1d ago
Avita Medical (RCEL) Stock Forum and DiscussionMoomoo report covering Avita Medical Inc. (RCEL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A live call on AVITA Medical’s third-quarter results is set for Nov. 5 at 1:30 p.m. Pacific.Stock Titan report covering Avita Medical Inc. (RCEL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Avita Medical (NASDAQ:RCEL) Stock Gets Price Target Increase from BTIG ResearchMarketBeat report covering Avita Medical Inc. (RCEL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
What AVITA Medical Holders Bought Into Before A 347% RunYahoo Finance report covering Avita Medical Inc. (RCEL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
AVITA Medical Q2 2026 Earnings Call TranscriptBenzinga report covering Avita Medical Inc. (RCEL) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
The Bet Behind AVITA Medical's 337% RunSimply Wall St report covering Avita Medical Inc. (RCEL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Traders Daily • 1d ago
How Avita Medical Inc. (RCEL) Affects Rotational Strategy TimingStock Traders Daily report covering Avita Medical Inc. (RCEL) market action, institutional positioning, and fundamental catalysts.
CATALYSTSeekingAlpha • 9d ago
The Most Negative Momentum Signal For 2026 Meets The Q4 Rally CycleMarket momentum is deeply negative, but Q4 rallies may favor value, dividends, and select cyclicals. Click for a look at the current state of the market and where it may be headed.
RISK WATCHYahoo • 13d ago
AVITA Medical to Announce Third Quarter 2026 Financial ResultsVALENCIA, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, to
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RCEL)
- ✓Walkthrough of RCEL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
RCEL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +265.65%▲ ASCENDING CHANNEL
2026-11-03O $16.71H $16.71L $15.65C $15.65VOL 597.1K
RES: $17.20SUP: $5.59SMA50: $12.46SMA200: $6.68
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
RCEL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +11.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on RCEL today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for RCEL. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RCEL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RCEL)
Health Care Rank #332 of 1015
⚔️ DCTH vs RCEL Full Matrix →
1. Head-to-Head Health Care Peer Comparison (RCEL vs. DCTH, SSII, SENS, ANGO)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Avita Medical Inc. (RCEL) ranks #332 by composite RQD confidence (46/100, grade D) and #449 by equity capitalization ($484.0M). Within this direct 5-issuer industry benchmark cohort, RCEL leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. DCTH currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with RCEL at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RCEL
ACTIVE
Avita Medical Inc. | D | 46/100 | — | 82.1% | -35.0% | -6.34% | $484.0M | Benchmark Subject |
| DCTH Delcath Systems Inc. | C- | 59/100 | — | 86.2% | 0.8% | -4.10% | $487.2M | /dcth-vs-rcel → |
| SSII SS Innovations International Inc. | E | 30/100 | — | 46.0% | -18.5% | -1.26% | $471.1M | /ssii-vs-rcel → |
| SENS Senseonics Holdings Inc. | D- | 40/100 | — | 44.7% | -35.0% | -2.46% | $502.8M | /sens-vs-rcel → |
| ANGO AngioDynamics Inc. | D- | 36/100 | — | 54.6% | -23.4% | -2.91% | $504.2M | /ango-vs-rcel → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001762303 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Avita Medical Inc. (RCEL) reported GAAP revenue of $71.6M (+11.5% vs. FY2024 revenue of $64.3M , and +42.8% cumulative change since FY2023) , GAAP net income of -$48.6M, operating cash flow of -$31.2M, and free cash flow of -$32.2M (+44.5% YoY). On the balance sheet, RCEL closed FY2025 with $56.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $71.6M | -$48.6M | -$31.2M | -$32.2M | $56.4M | $0 |
| FY2024 (FY) | 2024-12-31 | $64.3M | -$61.8M | -$48.9M | -$58.1M | $79.7M | $42.2M |
| FY2023 (FY) | 2023-12-31 | $50.1M | -$35.4M | -$38.0M | -$38.0M | — | — |
3. RCEL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs RCEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Avita Medical Inc. (NASDAQ: RCEL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $15.65 (-6.34% 1D, market cap $484.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RCEL ranks #332 in composite RQD confidence.
How does RCEL compare to DCTH and SSII in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), RCEL carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of 82.1%, and ROIC of -35.0%. By comparison, DCTH (Delcath Systems Inc.) holds a C- grade (59/100 RQD, P/E N/A, ROIC 0.8%, cap $487.2M) and SSII (SS Innovations International Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -18.5%, cap $471.1M). Among the 5-stock peer group, RCEL leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for RCEL?
Per RCEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001762303), Avita Medical Inc. generated $71.6M in revenue (+11.5% YoY), -$48.6M in net income, and -$32.2M in free cash flow against $56.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is RCEL trading relative to its 50-day, 200-day, and 52-week technical levels?
RCEL last traded at $15.65 (-6.34% on volume of 597,088 shares), positioning the stock +25.60% above its 50-day simple moving average ($12.46) and +134.28% above its 200-day simple moving average ($6.68). Across its 52-week range of $3.22 to $16.90, RCEL sits at the 90.9% percentile with a 14-day RSI of 61.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($13.69 to $17.61).
ROARABLE RATING BRIEF • RQD 46/100 (D)
✓ SEC XBRL & RQD VERIFIED
RCEL — Avita Medical Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Avita Medical Inc. (RCEL) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $15.65 (-6.34% 1D, market capitalization $484.0M).
- Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 82.1%, operating margin of -59.4%, and free cash flow yield of -6.23%.
- Whale 13F & Options Flow (16/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Avita Medical Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. Per the market data, the company reports a gross margin of 82.1%, indicating high gross profit per dollar of revenue. Per the financials, FY 2025 revenue was $71.6M.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Avita Medical Inc. (RCEL) reported $71.6M in annual revenue (up from $64.3M in FY2024, +11.5% YoY) and -$48.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($50.1M revenue, -$35.4M net income) through FY2025, RCEL scaled operating cash flow to -$31.2M and free cash flow to -$32.2M, backed by $56.4M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D • RQD 46/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -6.23% and institutional whale pillar of 16/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $3.22 – $16.90 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -59.4% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
No upstream or downstream links are recorded, and no proprietary signals are present.
- Key Question #1: Can RCEL sustain or expand its -59.4% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $71.6M and free cash flow of -$32.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is RCEL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
RCEL Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Avita Medical Inc. (RCEL) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 22h ago
AVITA Medical, Inc. (RCEL) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Avita Medical Inc. (RCEL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Moomoo • 1d ago
Avita Medical (RCEL) Stock Forum and Discussion Moomoo report covering Avita Medical Inc. (RCEL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A live call on AVITA Medical’s third-quarter results is set for Nov. 5 at 1:30 p.m. Pacific. Stock Titan report covering Avita Medical Inc. (RCEL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Avita Medical (NASDAQ:RCEL) Stock Gets Price Target Increase from BTIG Research MarketBeat report covering Avita Medical Inc. (RCEL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
What AVITA Medical Holders Bought Into Before A 347% Run Yahoo Finance report covering Avita Medical Inc. (RCEL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
AVITA Medical Q2 2026 Earnings Call Transcript Benzinga report covering Avita Medical Inc. (RCEL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
The Bet Behind AVITA Medical's 337% Run Simply Wall St report covering Avita Medical Inc. (RCEL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Traders Daily • 1d ago
How Avita Medical Inc. (RCEL) Affects Rotational Strategy Timing Stock Traders Daily report covering Avita Medical Inc. (RCEL) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
RCEL Bull vs. Bear Conversation Board — What's Your Call at $15.65?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RCEL 🐻 33% BEARISH CONVICTION
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH
🎯 Target: $18.15 (+16.0%)
📌 Pinned Debate Institutional whale flow scores 16 / 20 and the stock has rallied from a $3.22 52-week low to $16.71, with revenue growing from $50.1M
Picked up a starter position in RCEL in my $100K Virtual Cash book at $15.65. Institutional whale flow scores 16 / 20 and the stock has rallied from a $3.22 52-week low to $16.71, with revenue growing from $50.1M to $71.6M since FY 2023.. Trading inside a $3.22–$16.90 52-week range with -6.23% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.
SectorRotator 🐂 BULL
@BreakoutHunter Agree on the RQD 46/100 quality, though with 1.0 beta I'm scaling in with half-size at $15.65 and keeping dry powder in case we test $14.55.
MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH
🎯 Target: $12.36 (-21.0%)
Spot @ $15.65 Operating losses persist across all three reported periods with ROIC at -35% and FCF yield at -6.23%, while insider conviction scores o
Here is the bear case nobody on the bull side wants to address on RCEL: Operating losses persist across all three reported periods with ROIC at -35% and FCF yield at -6.23%, while insider conviction scores only 3 / 20.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.